Topic Hub
7 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 7 of 7 clinical reviews.
Clinical review of suvorexant (Belsomra) safety signals in FDA FAERS data, including the 2019 boxed warning for complex sleep behaviors, next-day somnolence, sleep paralysis, and suicidal ideation reports.
Read clinical reviewComplete regulatory history of Belsomra (suvorexant), the first dual orexin receptor antagonist approved by the FDA. Covers clinical trials, advisory committee votes, label changes, and post-market safety data.
Read clinical reviewA comprehensive review of suvorexant (Belsomra) regulatory approvals worldwide, including FDA scheduling, EMA assessment, Japanese approval, label requirements, and post-market safety surveillance data.
Read clinical reviewA clinical comparison of how the FDA approved suvorexant (Belsomra) and why the EMA took a different path, including dose selection, advisory committee debates, label warnings, and post-market safety data.
Read clinical reviewA complete review of every FDA label change to Belsomra (suvorexant) from 2020 through 2026, including new safety language, dosing guidance, and post-market surveillance findings reviewed and signed off by the HealthRX.com medical team.
Read clinical reviewA clinical review of suvorexant (Belsomra) regulatory history, patent litigation, FDA dose controversies, label restrictions, and post-market safety surveillance data.
Read clinical reviewFDA regulatory history of suvorexant (Belsomra), current label details, post-market safety data, and the next generation of dual orexin receptor antagonists in development.
Read clinical review